Loading
60 Degrees Pharmaceuticals, Inc. Stock: price and insider trades · United States
US·Mcap US$3.4M
No insider purchase over the last 90 days. The latest was filed 15 Jun 2026.
60 Degrees Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at 60 Degrees Pharmaceuticals, Inc. as filed with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 3 filings came from 1 insider.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €14k, made by 1 insider. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €7,642 from Dow Geoffrey S, disclosed on 12 December 2025. Among those who bought: 1 chief executive.
The last purchase on record was published on 15 June 2026, which is 124 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 3 filings, this issuer sits below that mark. Looking back to 2024, when coverage begins, insiders filed 10 purchases and no sales.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
24
Thresholds
n/a
Buy Volume
€132,658
10 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGeoffrey S. Dow5 buys
Cheryl Xu2 buys
Since the insiders bought
- -38.4%Entry US$1.46 · Close at T+90 US$0.90
- -87.8%Entry US$11.68 · Close at T+365 US$1.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.97
Analyst consensus
1 analysts2.00/5
US$3.70Target US$3.70(+283%)US$3.70
Income statement
RevenueUS$1M
Gross profitUS$223.8k22% margin
EBITDA-US$7.3M-724% margin
Net income-US$7.4M-732.5% margin
Valuation
PER (forward)-0.3x
Beta2.40
Balance sheet & cash
Market capUS$3.4M
Total debtUS$152.8k
Free Cash Flow-US$7.1M
Debt / Equity6%
Profitability & ownership
ROE-332.9%
ROA-127.1%
% insiders19.4%
% institutions17.1%
Last declaration on 15 June 2026
Declarations24 total
7,350 sharesCommon StockSEC:0001213900-26-068853:0
Canonical exit: 10 Sept 2026 (T+90)
9,670 shares@ US$0.80247.8% of flowCommon StockSEC:0001213900-25-122379:0
Canonical exit: 15 Mar 2026 (T+90)
9,350 shares@ US$0.95049.1% of flowCommon StockSEC:0001213900-25-120948:0
Canonical exit: 10 Mar 2026 (T+90)
7,201 shares@ US$1.388110.1% of flowCommon StockSEC:0001213900-25-087681:0
4,540 shares0Common StockSEC:0001213900-25-076983:0
4,376 shares@ US$2.985513.6% of flowCommon StockSEC:0001213900-25-052709:0
11,626 shares0Common StockSEC:0001213900-25-005051:0
14,394 shares0Common StockSEC:0001213900-25-005055:0
17,549 shares@ US$1.112322.0% of flowCommon StockSEC:0001213900-24-107011:0
Canonical exit: 5 Mar 2025 (T+90)
2,500 shares@ US$0.89922.5% of flowCommon StockSEC:0001213900-24-101110:0
Canonical exit: 17 Feb 2025 (T+90)
4,000 shares@ US$0.223100.0% of flowCommon StockSEC:0001213900-24-045706:0
4,000 shares@ US$0.223100.0% of flowCommon StockSEC:0001213900-24-045708:0
60,000 shares@ US$0.266882.9% of flowCommon StockSEC:0001213900-24-045707:0
17,000 shares@ US$0.2234.1% of flowCommon StockSEC:0001213900-24-045705:1
15,000 shares@ US$0.22317.1% of flowCommon StockSEC:0001213900-24-045707:1
68,000 shares@ US$0.266820.1% of flowCommon StockSEC:0001213900-24-045705:0
4,000 shares@ US$0.223100.0% of flowCommon StockSEC:0001213900-24-045704:0
45,560 shares@ US$4.745100.0% of flowCommon Stock, $0.0001 par value per share ("Common Shares")SEC:0001140361-24-017682:0
25,974 shares@ US$0.37510.7% of flowCommon StockSEC:0001213900-24-009603:0
Canonical exit: 30 Apr 2024 (T+90)
24 of 24 declarations
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a company focused on developing innovative pharmaceutical treatments. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
